ALK Fusion Protein Expression Terminated Phase 2 Trials for Capmatinib (DB11791)

IndicationStatusPhase
DBCOND0090278 (ALK Fusion Protein Expression)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02587650Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV MelanomaTreatment